Advanced Bladder Cancer VL

Outcomes with Immune Checkpoint Inhibitors in Patients with MTAP Alterations in Advanced Urothelial Carcinoma - Rafee Talukder

Details
Rafee Talukder discusses his presentation on his research into the effects of MTAP loss on survival rates among advanced urothelial cancer patients undergoing immunotherapy. With the help of an extensive international database, his team found that patients with this MTAP loss exhibited worse observed response rates and a trend toward poorer progression-free survival. In addition, the conversation...

A Breakthrough in Urothelial Cancer Treatment: Enfortumab Vedotin Combination Therapy - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg

Details
Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible populati...

Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre Zlotta

Details
Leslie Ballas, Jason Efstathiou, and Alexandre Zlotta discuss the study Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis'. The research suggests TMT is as effective as radical cystectomy, exhibiting no significant disparity in five-year survival rates. This implies TMT could be a valuable alternat...

New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with Second-Line Immune Checkpoint Inhibitors - Beyond the Abstract

Details
Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients with advanced urothelial cancer (aUC) progressing after platinum-based chemotherapy. Existing algorithms may not be sufficient following the introduction of immunotherapy. Our aim was to develo...

The San Raffaele Urologic Oncology Retreat: Examples of ECOG-ACRIN Research Initiatives - Petros Grivas

Details
Petros Grivas elaborates on the structure, work, and initiatives of the ECOG-ACRIN Cooperative Group, emphasizing its diverse committees and its collaboration with the NCI. He highlights the Group's exploration of targeted therapies and non-immunotherapy combinations, especially through their innovative ComboMATCH program, designed to overcome resistance to single-agent targeted therapies. Grivas...

The TAR-200 Device in Muscle-Invasive Bladder Cancer: Safety, Efficacy, and Future Prospects - Mark D. Tyson, II

Details
In this conversation, Sam Chang discusses a publication with Mark Tyson that focuses on the use of the TAR-200 device in patients with muscle-invasive bladder cancer. The study aimed to understand the safety, tolerability, and preliminary efficacy of the device in patients who were not suitable for radical cystectomy or radiation therapy. The initial findings showed that the device was well-tolera...

Addressing Challenges in Bladder Cancer Surgery: Enhancing Patient Outcomes and Preparing for Recovery - Sarah Psutka

Details
In this discussion, Zach Klaassen and Sarah Psutka focus on muscle-invasive bladder cancer and the challenges faced by high-risk patients undergoing radical cystectomy. They discuss the complexities of the surgery, including the reconstructive and bowel components, as well as the comorbidities and frailty commonly observed in bladder cancer patients. The importance of evaluating social support and...

Full Data Analysis of the Biology and Performance of Pre- and Post-Pembrolizumab VI-RADS for Predicting Pathological Response in MIBC: Insights from a Comprehensive Clinical Trials Pipeline - Andrea N...

Details
In this conversation, Ashish Kamat welcomes Andrea Necchi to present his research on the Vesical Imaging-Reporting and Data System (VI-RADS) and its correlation with the pathologic and molecular outcomes of patients undergoing perioperative IO therapy in the context of the PURE-01 study. The study focuses on the evaluation of MRI data and the response to neoadjuvant Pembrolizumab in muscle-invasiv...

Pros and Cons of Organ-Sparing Cystectomy in Bladder Cancer Patients: Balancing Oncologic and Functional Outcomes - Param Mariappan & Maria Carmen Mir

Details
In this conversation hosted by Ashish Kamat, Professors Param Mariappan and Maria Carmen Mir debate the pros and cons of organ-sparing cystectomy in bladder cancer patients. Professor Param Mariappan opposed the motion of organ preservation, highlighting the challenges and complexities associated with preserving reproductive organs for continence and sexual function. He discussed the limitations o...

Long-Term Results of the IMvigor130 Study: Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer – Matthew Galsky

Details
Matt Galsky joins Sam Chang in a conversation about the long-term results of the IMvigor130 randomized phase III study which evaluated the use of atezolizumab in combination with platinum/gemcitabine chemotherapy versus platinum/gemcitabine chemotherapy alone in patients with metastatic urothelial carcinoma. The study used a hierarchical statistical analysis plan, and the first analysis showed a s...